PE20230301A1 - Polipeptidos, composiciones y su uso para tratar o limitar el desarrollo de una infeccion - Google Patents
Polipeptidos, composiciones y su uso para tratar o limitar el desarrollo de una infeccionInfo
- Publication number
- PE20230301A1 PE20230301A1 PE2022001743A PE2022001743A PE20230301A1 PE 20230301 A1 PE20230301 A1 PE 20230301A1 PE 2022001743 A PE2022001743 A PE 2022001743A PE 2022001743 A PE2022001743 A PE 2022001743A PE 20230301 A1 PE20230301 A1 PE 20230301A1
- Authority
- PE
- Peru
- Prior art keywords
- polypeptides
- infection
- treat
- development
- limit
- Prior art date
Links
- 229920001184 polypeptide Polymers 0.000 title abstract 3
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 3
- 208000015181 infectious disease Diseases 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 2
- 241001678559 COVID-19 virus Species 0.000 abstract 1
- 230000005875 antibody response Effects 0.000 abstract 1
- 239000002105 nanoparticle Substances 0.000 abstract 1
- 230000003389 potentiating effect Effects 0.000 abstract 1
- 230000001681 protective effect Effects 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Communicable Diseases (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Pulmonology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062977036P | 2020-02-14 | 2020-02-14 | |
| US202063046159P | 2020-06-30 | 2020-06-30 | |
| US202063064235P | 2020-08-11 | 2020-08-11 | |
| PCT/US2021/017799 WO2021163438A1 (en) | 2020-02-14 | 2021-02-12 | Polypeptides, compositions, and their use to treat or limit development of an infection |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20230301A1 true PE20230301A1 (es) | 2023-02-13 |
Family
ID=74873805
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2022001743A PE20230301A1 (es) | 2020-02-14 | 2021-02-12 | Polipeptidos, composiciones y su uso para tratar o limitar el desarrollo de una infeccion |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20240277831A1 (https=) |
| EP (1) | EP4103230A1 (https=) |
| JP (1) | JP2023513720A (https=) |
| KR (1) | KR20220142472A (https=) |
| CN (1) | CN116096404A (https=) |
| AU (1) | AU2021221139A1 (https=) |
| BR (1) | BR112022016220A2 (https=) |
| CA (1) | CA3167318A1 (https=) |
| CO (1) | CO2022011467A2 (https=) |
| MX (1) | MX2022009860A (https=) |
| PE (1) | PE20230301A1 (https=) |
| PH (1) | PH12022552099A1 (https=) |
| WO (1) | WO2021163438A1 (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12194089B2 (en) | 2020-02-04 | 2025-01-14 | CureVac SE | Coronavirus vaccine |
| US11241493B2 (en) | 2020-02-04 | 2022-02-08 | Curevac Ag | Coronavirus vaccine |
| JP2023521418A (ja) | 2020-04-10 | 2023-05-24 | インビビド， インコーポレイテッド | コロナウイルスｓタンパク質に特異的な化合物及びその使用 |
| WO2022016122A2 (en) * | 2020-07-17 | 2022-01-20 | Tonix Pharmaceuticals Holding Corp. | Skin-based testing for detection of cell-mediated immune responses to sars-cov-2 |
| US11918643B2 (en) | 2020-12-22 | 2024-03-05 | CureVac SE | RNA vaccine against SARS-CoV-2 variants |
| US20220324918A1 (en) * | 2021-03-30 | 2022-10-13 | Regents Of The University Of Minnesota | SARS-CoV-2 SPIKE ECTODOMAIN POLYPEPTIDES AND COMPOSITIONS AND METHODS THEREOF |
| WO2023034991A1 (en) * | 2021-09-02 | 2023-03-09 | Kansas State University Research Foundation | Mrna vaccine formulations and methods of using the same |
| US20240385189A1 (en) * | 2021-09-10 | 2024-11-21 | Jacobs Technion-Cornell Institute | Compositions and methods for determining humoral immune responses against seasonal coronaviruses and predicting efficiency of sars-cov-2 spike targeting, covid-19 disease severity, and providing interventions |
| KR102527221B1 (ko) * | 2021-10-15 | 2023-05-02 | 에스케이바이오사이언스 주식회사 | 단백질의 정제방법 |
| KR102621026B1 (ko) * | 2021-10-15 | 2024-01-09 | 에스케이바이오사이언스(주) | 단백질의 정제방법 |
| KR102524839B1 (ko) * | 2021-11-04 | 2023-04-25 | 에스케이바이오사이언스(주) | 사스-코로나바이러스-2 감염증 예방 또는 치료용 백신 조성물 |
| US20250000968A1 (en) * | 2021-11-12 | 2025-01-02 | The United States of America, as represented by the Secretary,Department of Health and Human Service | Sars-cov-2 spike fused to a hepatitis b surface antigen |
| WO2023122257A2 (en) * | 2021-12-22 | 2023-06-29 | La Jolla Institute For Immunology | Coronavirus spike glycoprotein with improved expression and stability |
| CN114656571B (zh) * | 2022-02-18 | 2024-07-16 | 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） | 一种四价SARS-CoV-2嵌合纳米颗粒疫苗及其制备方法与应用 |
| US20240207389A1 (en) * | 2022-04-27 | 2024-06-27 | Northwestern University | Methods for improving covid vaccine immunogenicity |
| WO2024014943A1 (ko) * | 2022-07-12 | 2024-01-18 | 에스케이바이오사이언스 주식회사 | Sars-cov-2 백신 부스터 조성물 |
| WO2024076982A2 (en) * | 2022-10-05 | 2024-04-11 | University Of Washington | Pan-sarbecovirus nanoparticle vaccines |
| EP4608442A1 (en) | 2022-10-28 | 2025-09-03 | GlaxoSmithKline Biologicals S.A. | Nucleic acid based vaccine |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA017887B1 (ru) * | 2007-08-02 | 2013-03-29 | Байондвакс Фармасьютикалз Лтд. | Полимерные мультиэпитопные вакцины против гриппа |
| US10248758B2 (en) * | 2013-02-07 | 2019-04-02 | University Of Washington Through Its Center For Commercialization | Self-assembling protein nanostructures |
| CN105934441A (zh) * | 2013-11-26 | 2016-09-07 | 贝勒医学院 | 新型sars免疫原性组合物 |
| US9630994B2 (en) * | 2014-11-03 | 2017-04-25 | University Of Washington | Polypeptides for use in self-assembling protein nanostructures |
| US10676511B2 (en) * | 2015-09-17 | 2020-06-09 | Ramot At Tel-Aviv University Ltd. | Coronaviruses epitope-based vaccines |
| WO2018175560A1 (en) * | 2017-03-22 | 2018-09-27 | The Scripps Research Institute | Nanoparticle immunogens to elicit responses against the influenza receptor binding site on the hemagglutinin head domain |
| HUE073526T2 (hu) * | 2017-04-04 | 2026-01-28 | Univ Washington | Önmagát összeállító fehérje nanostruktúrák, amelyek paramyxovírus és/vagy pneumovírus F fehérjéket jelenítenek meg és azok használata |
| WO2019169120A1 (en) * | 2018-02-28 | 2019-09-06 | University Of Washington | Self-asssembling nanostructure vaccines |
-
2021
- 2021-02-12 WO PCT/US2021/017799 patent/WO2021163438A1/en not_active Ceased
- 2021-02-12 AU AU2021221139A patent/AU2021221139A1/en active Pending
- 2021-02-12 PE PE2022001743A patent/PE20230301A1/es unknown
- 2021-02-12 CA CA3167318A patent/CA3167318A1/en active Pending
- 2021-02-12 BR BR112022016220A patent/BR112022016220A2/pt unknown
- 2021-02-12 MX MX2022009860A patent/MX2022009860A/es unknown
- 2021-02-12 KR KR1020227031351A patent/KR20220142472A/ko active Pending
- 2021-02-12 CN CN202180028727.9A patent/CN116096404A/zh active Pending
- 2021-02-12 US US17/760,174 patent/US20240277831A1/en active Pending
- 2021-02-12 EP EP21711980.9A patent/EP4103230A1/en active Pending
- 2021-02-12 PH PH1/2022/552099A patent/PH12022552099A1/en unknown
- 2021-02-12 JP JP2022548783A patent/JP2023513720A/ja active Pending
-
2022
- 2022-08-16 CO CONC2022/0011467A patent/CO2022011467A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PH12022552099A1 (en) | 2024-01-29 |
| CA3167318A1 (en) | 2021-08-19 |
| MX2022009860A (es) | 2022-11-07 |
| US20240277831A1 (en) | 2024-08-22 |
| EP4103230A1 (en) | 2022-12-21 |
| AU2021221139A1 (en) | 2022-09-01 |
| KR20220142472A (ko) | 2022-10-21 |
| CO2022011467A2 (es) | 2022-10-31 |
| CN116096404A (zh) | 2023-05-09 |
| BR112022016220A2 (pt) | 2022-10-25 |
| JP2023513720A (ja) | 2023-04-03 |
| WO2021163438A1 (en) | 2021-08-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20230301A1 (es) | Polipeptidos, composiciones y su uso para tratar o limitar el desarrollo de una infeccion | |
| LIU et al. | The recombinant N-terminal region of human salivary mucin MG2 (MUC7) contains a binding domain for oral Streptococci and exhibits candidacidal activity | |
| AR123978A1 (es) | Variantes de la interleucina-18 y métodos de uso | |
| ES2562157T3 (es) | Vacuna multiepitópica contra los cánceres asociados con Her2/neu | |
| AR064555A1 (es) | Peptido wt1 restringido a hla-a*1101 y composicion farmaceutica que comprende el mismo | |
| PE20130588A1 (es) | Hepcidina, antagonistas de la hepcidina y metodos de uso | |
| AR108442A1 (es) | Proteínas de fusión gdf15 y usos de estas | |
| KR960703942A (ko) | 사람 융모막 고나도트로핀의 항원성을 갖는 화합물(Compounds having the antigenicity of hCG) | |
| CY1113218T1 (el) | Υβριδιο και διμερης εκφραση πρωτεϊνων ναϊσσεριας | |
| AR047729A1 (es) | Anticuerpos terapeuticos que se unen a la apolipoproteina e (apoe) | |
| AR076349A1 (es) | Peptido auxiliar del antigeno del cancer | |
| JOP20240283A1 (ar) | تركيبة منظف الشعر وفروة الرأس لإزالة السموم، طرق استخدامها واستخداماتها | |
| BRPI0815578B8 (pt) | Peptídeo de cdca1, seu uso e composição imunogênica compreendendo o mesmo para induzir imunidade, tratar e/ou prevenir o câncer, bem como método in vitro para induzir uma célula apresentadora de antígeno e uma célula t citotóxica (killer) | |
| Sutoh et al. | Actin-fragmin interactions as revealed by chemical cross-linking | |
| PE20251671A1 (es) | Anticuerpos antagonistas de il-18bp y su uso en monoterapia y terapia de combinacion en el tratamiento del cancer | |
| CU24746B1 (es) | Apirasas humanas, solubilizadas y modificadas útiles para prevenir y tratar el daño tisular | |
| AR035387A1 (es) | Molecula de adn que codifica una udp-glucosa: aglicon-glucosiltransferasa, udp-glucosa: aglicon-glucosiltransferasa, metodo para el aislamiento de una molecula de adnc que codifica una udp-glucosa: aglicon-glucosiltransferasa, metodo para producir udp-glucosa: aglicon-glucosiltransferasa recombinant | |
| PE20240492A1 (es) | Vacuna heterologa de estimulo primario | |
| PE20231442A1 (es) | Proteinas actrii y sus usos | |
| Eckerskorn et al. | In the uncoupling protein from brown adipose tissue the C-terminus protrudes to the c-side of the membrane as shown by tryptic cleavage | |
| CY1105683T1 (el) | Ενεργο συζυγες ακανθοχοιρικης πρωτεϊνης, μεθοδος για την παρασκευη και χρηση αυτου | |
| AR070177A1 (es) | COMPOSICIONES BACTERIANAS QUE COMPRENDEN PROTEíNAS PERTENECIENTES AL GRUPO DE RECEPTORES DE RECONOCIMIENTO DE PATRONES (PRR) QUE PRESENTAN UN DOMINIO DE REPETICIoN DE LEUCINA (RRL) | |
| AR132053A1 (es) | Composiciones para su uso en el tratamiento de clamidia | |
| BR112022026248A2 (pt) | Conjugados de citocinas | |
| JP2025503079A5 (https=) |